BRAF and melanoma: Indeed, while it is known that MAPK/ERK signaling is involved in MiTF turnover and activation, with a crucial contribution of BRAF-mediated transcriptional and post-transcriptional regulation (32, 33), the recently discovered ERK-mediated signaling pathway that controls TFEB in BRAFV600E-driven melanoma does not work in the same way for either MiTF or TFE3 (26).